USFDA completes inspections at Suven Pharma facilities with no form 483

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-02-24T11:45:18+05:30 | Updated On 21 March 2024 3:49 PM IST

Dr Reddys Bollaram Unit gets 7 USFDA Observations

Hyderabad: Suven Pharma has announced that the US Food & Drug Administration (US FDA) has completed the inspections at the Company's Pashamylaram facilities.

The inspection was conducted from February 12, 2024, to February 23, 2024.

"This is to inform you that our Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the PreApproval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today," the Company informed in a BSE filing.

"We are pleased to inform you that no Form 483 has been issued as a result of the inspection," Suven added.

USFDAUSFDA inspectionsuven pharmasuven pharma news

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751